



Subcutaneous Antibiotic Therapy: The Why, How, Which Drugs and When

Virgilio Hernández-Ruiz, Emmanuel Forestier, Gaëtan Gavazzi, Tristan Ferry, Nicolas Grégoire, Dominique Breilh, Marc Paccalin, Sylvain Goutelle, Claire Roubaud-Baudron

► To cite this version:

Virgilio Hernández-Ruiz, Emmanuel Forestier, Gaëtan Gavazzi, Tristan Ferry, Nicolas Grégoire, et al.. Subcutaneous Antibiotic Therapy: The Why, How, Which Drugs and When. Journal of the American Medical Directors Association, 2021, 22 (1), pp.50-55.e6. 10.1016/j.jamda.2020.04.035 . hal-03194481

HAL Id: hal-03194481

<https://hal.science/hal-03194481>

Submitted on 2 Jan 2023

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution - NonCommercial 4.0 International License

Title

Subcutaneous antibiotic therapy: the why, how, which drugs and when

Intended Category

Narrative Review

Authors

Virgilio Hernández-Ruiz M.D.^{a,b}, Emmanuel Forestier M.D.^c, Gaëtan Gavazzi M.D.,
Ph.D.^d, Tristan Ferry M.D., Ph.D.^e, Nicolas Grégoire M.D., Ph.D.^{f,g}, Dominique Breilh
D.Pharm., Ph.D.^{h,i}, Marc Paccalin M.D., Ph.D.^{j,k}, Sylvain Goutelle D.Pharm., Ph.D.^{l,m},
Claire Roubaud-Baudron M.D., Ph.D.^{b,n} on behalf of the GInGer (Groupe Infectio-
Gériatrie)

- a) Instituto Nacional de Ciencias Médicas y Nutrición “Salvador Zubirán”. Mexico
City, Mexico.
- b) CHU de Bordeaux, Pôle de Gériatologie Clinique, F-33 000 Bordeaux, France
- c) Service de Maladies Infectieuses, CH Métropole Savoie, F-73000 Chambéry,
France
- d) GREPI EA7408 Université de Grenoble-Alpes et Service universitaire de
Gériatrie clinique, CHU Grenoble-Alpes.
- e) Hospices Civils de Lyon, Services de maladies infectieuses, Univ. Claude
BERNARD Lyon 1, F-69000 Lyon
- f) Inserm U1070, Poitiers, France ; Université de Poitiers, UFR Médecine-
Pharmacie, Poitiers, France
- g) Service de Toxicologie et Pharmacologie, CHU Poitiers, F-86000 Poitiers,
France

- h) Laboratoire de Pharmacocinétique et de Pharmacie Clinique- Groupe PK/PD -
INSERM U1034, Université de Bordeaux, F-33000 Bordeaux, France
- i) Unité de Pharmacie Clinique coordination ville-hôpital, CHU de Bordeaux, F-
33000 Bordeaux, France
- j) Pôle de Gériatrie, CHU Poitiers, Univ. Poitiers, F-86000 Poitiers, France
- k) Centre d'Investigation Clinique CIC 1402, INSERM CHU Poitiers, Univ.
Poitiers, F-86000 Poitiers, France
- l) Hospices Civils de Lyon, Groupement Hospitalier Nord, Service de Pharmacie,
F-69000 Lyon, France
- m) Univ. Lyon 1, UMR CNRS 5558, Laboratoire de Biométrie et Biologie
Évolutive & Faculté de Pharmacie de Lyon, F-69000 Lyon, France
- n) Univ. Bordeaux, INSERM UMR 1053 BaRITOn, F-33 000 Bordeaux, France

Corresponding author: Claire Roubaud-Baudron, M.D., Ph.D.

Hôpital Xavier Arnoz, CHU Bordeaux Avenue du Haut Leveque

33604 Pessac Cedex, France claire.roubaud@chu-bordeaux.fr

Tel : + 33 (0) 5 57 65 65 57 & Fax : + 33 (0) 5 57 65 65 60

Running title: Subcutaneous antibiotic therapy

Key words: Subcutaneous, subcutaneously administered, antibiotics, antimicrobials

Funding sources: This research did not receive any funding from agencies in the public, commercial, or not-for-profit sectors.

Abstract length: 239 words

Article length: 2970 words, 1 table, 1 figure, 1 appendix.

Brief summary:

This study reports the rationale for subcutaneous (SC) administration of antibiotics and its limitations. Evidence suggests that the SC route could be an alternative to the IV route for time-dependent antibiotics in specific situations.

Abstract

Objectives: To describe the rationale for subcutaneous (SC) administration of antibiotics from available published data and to make propositions to help clinicians in daily practice.

Design: Narrative review

Setting and participants: Hospitalized patients, persons in long-term care facilities and ambulatory care.

Methods: We searched the MEDLINE/PubMed electronic database for evidence supporting SC administration of antibiotics, up to September 2019; the results of this primary search were supplemented by searching the references of the identified articles, as well as by searching in Google Scholar.

Results: Regarding tolerability, efficacy, and pharmacokinetic/pharmacodynamic (PK/PD) profiles, most studies suggest that the SC route could be an alternative to the IV route, particularly for time-dependent antibiotics and among certain patient populations, like patients with poor venous access, swallowing disorders or behavioural disturbance. However, clinical evidence of the benefits and risks of SC antibiotic administration is still scarce and of low level.

Conclusions and Implications: SC administration of antibiotics may be useful in various settings such as in hospitalized patients and among those in long-term care facilities or being cared for at home. However, further clinical studies are needed to assess the PK/PD properties, as well as the risks and benefits of SC administration of antibiotics. In this review, we highlight the potential benefits of SC administration of antibiotics and address practical recommendations for its use. This information will

- 24 enable improvement of treatment strategies and present the SC route as a potential
- 25 option in specific situations.

Subcutaneous antibiotic therapy: Why, how, which drugs, and when

Introduction

Bacterial infections are one of the main causes of morbidity and mortality in the older population and pose many challenges to the clinician; one of the first challenges is selecting the route of antibiotic administration. The most frequently used routes for delivering antibiotics are intravenous (IV), oral, and intramuscular (IM), each one with benefits and drawbacks.¹

In special populations like older adults, an IV access may become challenging because of a poor peripheral venous network or agitation. IM access can be associated with pain and is contraindicated in patients receiving anticoagulants. Moreover, drugs administered through IM route can inadvertently be delivered to the subcutaneous (SC) space.^{2, 3, 4, 5} Oral administration may be compromised by swallowing disorders, altered mental state, or by limited treatment options. In addition, the oral bioavailability of certain antibiotics may be reduced by food-drug, drug-drug interactions, and gastrointestinal disorders.^{2, 3, 4}

SC administration may help to circumvent those limitations frequently found in long-term care facilities, geriatric departments, palliative, and ambulatory care, which could partially explain why this route is mainly used in those settings.⁶ Nevertheless, SC administration of antibiotics is still off-label for many of them. An up-to-date review on this issue is needed as a growing body of evidence could further support the use of the SC route.^{7, 8, 9, 10} The main objectives of this review were to analyse the rationale for SC administration of antibiotics, and make practical propositions to help clinicians in daily practice, as well as the development of future clinical trials.

Methods

We conducted a MEDLINE/PubMed database research up to September 2019, the results of this primary search were supplemented by reviewing the references of the identified articles, and by searching Google Scholar. The initial PubMed search terms were: subcutaneous[All Fields] AND ("anti-bacterial agents"[Pharmacological Action] OR "anti-bacterial agents"[MeSH Terms] OR ("anti-bacterial"[All Fields] AND "agents"[All Fields]) OR "anti-bacterial agents"[All Fields] OR "antibiotic"[All Fields])) AND "humans"[MeSH Terms]. The initial search provided close to 500 articles. Any abstract that described SC administration of antibiotics in humans was considered eligible for inclusion. Abstracts that did not described SC administration of antibiotics, and animal-based studies were excluded. Posters and conference presentations were included if they described original research. The articles considered for inclusion were limited to those written in French, English, or Spanish. Finally, 37 articles, and 3 poster presentations were included.

Discussion

Why subcutaneous administration?

- The subcutaneous route

Drugs administered by SC route are delivered into the interstitial space, a fibro-collagenous network beneath the dermis.¹¹ Following their delivery, one of the first things that influences absorption is molecular weight. Small-molecules are absorbed into the interstitial vasculature by passive diffusion and endothelial permeability. Whereas high-molecular-weight agents are absorbed in the lymphatic system, which delays the time to achieve their maximum concentration.^{12, 13} Other factors that influence the rate and extent of drugs absorption are: electric charge, hydrophilicity, degradation profile, and formulation (*e.g.*, concentration, volume, viscosity, and excipient profile).¹⁴ In clinical practice, the SC route is routinely used to administer

vaccines, insulin, heparin, biological agents, and high-molecular-weight medications (e.g., immunoglobulins).^{15, 16}

- **Advantages of subcutaneous administration**

The SC route may usefully combine some advantages of both the oral and other parenteral routes.^{17, 18} SC administration of drugs is described as easy to perform (less demanding for nursing staff), it enables continuous administration of fluids (hypodermoclysis), or bolus administration of pharmacological agents in diverse settings.^{19, 20, 21, 22} Also, compared to the IV route, the risks of thrombosis and catheter infections in SC route are less frequent or less severe, however strong evidence from comparative studies is lacking.^{9, 23} Unlike IM route, SC administration is not contraindicated by anticoagulant therapy, which is common in older adults. In addition, the SC route has little impact on patient's mobility, which is a central component for the prevention of functional decline and rehabilitation.²⁴

Taking into account the mentioned profile, SC administration of antibiotics could find a place in-hospital care, prolonged outpatient therapy, as well as in long-term care facilities.^{25, 26}

- **Limitations of subcutaneous administration**

Adverse events (AEs) caused by SC administration of drugs may include pain, oedema, and inflammation at the injection site (details for AEs are described in **Appendix**). Also, solutions with high osmolality and/or very low or high pH cannot be administered through SC route due to the risk of cutaneous necrosis.¹⁹ Reduced bioavailability (due to partial absorption) and potential underdosing are other relevant issues that should be considered when using the SC route.

- **Subcutaneous administration of antibiotics**

In some European countries, SC administration of antibiotics, although off-label, appears to be commonly considered by infectious diseases (ID) specialists and geriatricians.^{6, 27, 28, 29} In a survey of 382 French practitioners, 96% of participants reported SC administration of antibiotics at some point, and more than a third of the geriatricians surveyed reported administering SC antibiotics at least weekly. Concerning the type of antibiotic, ID specialists and geriatricians reported previous use of SC route for ceftriaxone (100%), ertapenem (33%), teicoplanin (39%), aminoglycosides (35%), and amoxicillin (15%).⁶ However, routine SC administration of antibiotics worldwide is infrequent.^{28, 29}

How is the subcutaneous route being used for the administration of antibiotics?

Results from a prospective observational multicentric study that included 219 patients treated with SC antibiotics, showed that SC antibiotics are most frequently diluted in 0.9% NaCl (72.3%), administered by slow injection; *i.e.*, > 5 min (61.3%), and using a flexible catheter (67.9%). The preferred injection sites were the thighs (51.7%) and flanks (25.1%). AEs were reported in 50 patients (22.8%), and included local pain (13.2%), induration (7.8%), hematoma (7.3%), and erythema (2.7%).²⁷ AEs were usually transient, and mainly reported with teicoplanin (70%). Administration of teicoplanin, and rapid injection (< 5 min), were both predictors of AEs. Antiplatelet or anticoagulant agents were not associated with AEs.²⁷ However, the principal limits of this survey were the sample size, participation on voluntary basis, and uncontrolled design.

Based on our daily experience and available evidence, clinical recommendations include checking the injection site daily to identify any local AEs. Regarding an optimal dilution, there is no strong evidence or consensus, and we currently use the same dilution as for the IV route. Administration of antibiotics diluted in 50–100 mL of

solvent (NaCl 0.9% or glucose 5%) by slow injection (by gravity; 30–60 min) and the use of a flexible catheter seems to decrease the risk of local AEs. Flexible catheters may be either removed between infusions, considering a change of injection site at each administration or kept patent for 3–4 days. While thighs and flanks are the preferred sites of injection, the back may be considered to prevent catheter removal by an agitated patient. Surveillance of spillage and catheter misplacement are also important.³⁰

Which antibiotics?

- Importance of pharmacokinetic/pharmacodynamic properties for SC antibiotic administration

The main PK/PD indices of antibiotics are: the minimum inhibitory concentration (MIC; minimum concentration of the antibiotic that inhibits bacterial growth), the minimal plasma or trough concentration (C_{min}), the peak concentration (C_{max}), time to reach C_{max} (T_{max}), the length of time during which the concentration of the drug is greater than the MIC ($T > MIC$), peak concentration divided by MIC (C_{max}/MIC), and the ratio of the 24 h area under the time-concentration curve divided by the MIC (AUC/MIC).^{32, 33, 34}

Normally, the progressive diffusion of a molecule from the SC space to the intravascular compartment is associated with a decrease in the peak plasma concentration (reduced C_{max}) and a longer time to achieve it (increased T_{max}), compared with intermittent IV administration. However, the area under the time-concentration curve may be similar to that obtained with the IV route if the dose is entirely absorbed, *i.e.*, if the SC bioavailability is close to 100% (**Figure 1**). Hence, the SC route may be associated with prolongation of the action of a drug, even though its terminal half-life is unchanged compared to IV route. The next sections of the article will focus on the available evidence that supports how the SC route may optimize the PK/PD parameters

of time-dependent antibiotics, like certain β -lactams. By contrast, SC administration is unlikely to optimize the PK/PD of concentration-dependent agents—e.g. aminoglycosides and fluoroquinolones—as their C_{max} would be decreased.³⁵ Findings of reports on SC administration of antibiotics are listed in **Appendix**, and summarised along with practical recommendations in **Table 1**. These recommendations are mainly based on PK/PD and safety data. An important consideration is the heterogeneity among studies in terms of design, objectives, populations, reports of AE, clinical, and PK data.

Ceftriaxone

Ceftriaxone is frequently administered SC in some European countries, possibly due to its spectrum, half-life, and previous marketing approval for SC route use until 2015. However, this route has been discouraged by the European Medicines Agency because of insufficient clinical data, so SC use is currently off-label.³⁶ Still, SC ceftriaxone is prescribed in settings such as hospitalization, ambulatory assistance and palliative care.^{27, 37, 38, 39, 40, 41, 42, 43} SC administration of ceftriaxone is associated with a lower peak concentration compared to IV administration, but its bioavailability approaches 100%.³⁹ Other PK parameters such as the trough level, AUC, and T>MIC (which is predictive of the efficacy of β -lactams), are adequate compared to the IV route.^{37, 38, 41, 42} Moreover, co-administration of ceftriaxone with recombinant hyaluronidase is associated with a higher C_{max} and reduced T_{max} .³⁹ Ceftriaxone is generally well tolerated; the most frequently reported AE is pain at the injection site, which may be ameliorated by previous application of lidocaine or recombinant hyaluronidase.^{27, 37} Rapid injection of ceftriaxone should be avoided as it increases pain.^{27, 38, 39} The available evidence for the efficacy and tolerability of ceftriaxone by SC route could support its use.^{27, 38, 40, 42} (**Appendix**).

Ertapenem

Ertapenem is mainly used to treat infections caused by Gram-negative bacteria that produce extended-spectrum β -lactamases (ESBL-E). SC administration of ertapenem has been studied, but its clinical use is off label. Frasca *et al.* reported that SC administration resulted in a lower C_{max} compared to IV administration, but the AUCs over the dosing interval were similar, which suggests a bioavailability close to 100%.⁴⁴ Similar findings have been reported for high-dose ertapenem in bone and joint infections (BJI).^{45, 46} Population PK/PD parameters and the results of simulations suggest that SC ertapenem has a comparable T>MIC index respect to IV route.²⁶ In a recent study of older persons (mean age, 86 years) with mainly urinary or respiratory tract infections, SC and IV ertapenem presented no significant differences in individual AUCs or the chosen PTA (probability of target attainment) of maintaining a $fT>MIC$ at least 40% of the time.³⁰ Forestier *et al.* has also reported successful SC use of ertapenem for urinary tract infections caused by ESBL-E.⁴⁷ Studies mainly report mild AEs with SC use of ertapenem, excepting one report of skin necrosis.^{26, 30, 44, 46} Therefore, SC administration of ertapenem could be considered as an alternative to IV administration. (Appendix).

- **Teicoplanin**

Teicoplanin is a glycopeptide used as an alternative to vancomycin for the treatment of infections caused by some Gram-positive bacteria. It has a long elimination half-life, and several days are necessary to achieve a steady-state concentration, which normally requires the use of loading doses during the first days of therapy.^{48, 49} Four studies have evaluated the tolerance and efficacy of SC teicoplanin. The first assessed the efficacy, tolerance, and PK of teicoplanin delivered by SC and IV routes; PK results showed that the C_{min} did not differ between IV and SC routes during the first 14 days of treatment.⁵⁰ In the second study, the SC route was used after an initial IV loading. Wherein IV route

resulted in a higher peak concentration, the C_{min} was higher at 48 h after SC administration.²⁵ The third study, mainly comprised by older patients with BJI, showed that 85% of participants achieved the target C_{min} irrespective of the route of administration (IM, IV, or SC).⁵¹ In addition, Cazaubon *et al.* showed that SC administration of teicoplanin was associated with a lower C_{min} and plasma concentration (AUC) after a 2-day loading phase, but these differences were absent after 14 days due to drug accumulation.^{52, 53} SC teicoplanin has also been used to treat infective endocarditis, however this has only been anecdotal.⁵⁴

The incidence of AEs after SC administration of teicoplanin ranges from 10% to 30% (mainly local pain). However, in the multicentric survey of Roubaud-Baudron *et al.*, SC teicoplanin was independently associated with AEs.²⁷ Similarly, El Samad *et al.* found that the frequency of SC teicoplanin-associated AEs increased for doses > 600 mg per day, suggesting that concentration could influence tolerance.²⁵ (**Appendix**).

- Aminoglycosides

Studies of SC administration of amikacin and tobramycin showed a lower C_{max} , higher T_{max} , and comparable bioavailability respect to IV administration. However, these studies are outdated and have methodological limitations; hence, their relevance to current clinical practice is limited.^{55, 56, 57, 58} C_{max} is an important PK parameter for these concentration-dependent antibiotics and SC route could decrease their efficacy. Amikacin, and gentamycin have poor local tolerability and a high rate of severe local AEs, including painful nodules, ulcers, and cutaneous necrosis.^{59, 60, 61, 62, 63} Currently, aminoglycosides are rarely administered by SC route, and the available evidence does not support their use.^{7, 8, 9, 27} (**Appendix**).

Other antibiotics

SC administration of ampicillin, cefepime, and temocillin present a similar PK profile to that of the other studied antibiotics, characterized by a delayed T_{max} but similar AUCs.^{55, 64, 65} However, these studies were performed in healthy volunteers and with single-dose PK analysis.

Some antibiotics—vancomycin, oxacillin, and cefuroxime—induce endothelial toxicity when administered IV, and may not be well tolerated when administered SC as their absorption would take place on interstitial vasculature.³¹

When to perform SC administration?

Current evidence shows that IV route represents the best option to initiate antibiotic therapy in severe infections (sepsis, septic shock), as therapeutic concentrations are rapidly achieved. However, switching from IV to SC once the patient has been stabilized is feasible, particularly for time-dependent antibiotics, provided that the AUCs and T>MIC values are comparable. In non-urgent situations, particularly when oral access is limited, initiating antibiotics by SC route could be discussed as an alternative.

Indications for SC administration of antibiotics are not standardized. In the previously described survey by Roubaud-Baudron *et al.*, in almost half the cases SC route was used as a switch from IV or oral routes.²⁷ Frequent reasons for SC administration were: poor venous access, palliative care, patient agitation, contraindications for oral and IM administration, and non-availability of a suitable oral antibiotic. Also, SC administration has been used to facilitate hospital discharge or prevent hospitalization.^{27, 29}

Infections requiring prolonged antibiotic administration, usually managed in hospital (*e.g.*, BJI or infective endocarditis), could benefit from SC route due to its safety, potential suitability for ambulatory care, easy supervision, and its PK and PD properties.

SC administration could be particularly useful for people with poor venous access, such as older adults and IV drug users. It could also be a resource to consider in persons with hyperactive delirium, and to prevent functional decline, as it poses less of a restraint to mobility than continuous IV lines. SC administration of antibiotics may also be considered in special conditions, including patients with an altered mental state, patients with swallowing disorders, and those receiving palliative care. It is not infrequent that in those patients, central venous catheters or peripherally inserted central catheters (PICC) are placed, being inappropriate as they are uncomfortable, and increase the risk of further complications like thrombosis or infection.

- **Future perspectives regarding SC administration**

The interest in SC administration of drugs is increasing in many specialties, and for diverse agents.⁶⁶ Therefore, multiple strategies for optimizing the efficacy and tolerance of SC administration are under development, such as the use of recombinant human hyaluronidase to decrease the diffusion barrier.^{67, 68, 69, 70} Also, interestingly, simple tools like mentholated warm compresses, may improve the SC blood flow rate and absorption of antibiotics.⁷¹

SC route may be a useful resource in the treatment of ambulatory patients in developing countries, as well as vulnerable patients (including IV drug users), people in remote locations and could also find applications in military medicine.

The absence of studies with clinical efficacy endpoints, adequate controls, large sample sizes, and the lack of analysis of PK/PD parameters limit the use of SC administration for most antibiotics. Still, studies focusing on PK/PD parameters and safety analysis of new routes for previously approved antibiotics may be appropriate for supporting (or

not) the use SC without necessarily conducting full comparative studies, as pointed in FDA guidelines and other publications.^{72, 73}

Future studies should be conducted taking in account special populations (obese, older, and malnourished patients), antibiotics administered more than once daily, or in continuous infusion. They should also have an adequate modelling to limit the number of biologic samples taken from the population, and with parallel-group or crossover designs. Some current initiatives are already trying to address the main limitations.⁷⁴

The potential advantages of SC administration of antibiotics must not override compliance with good clinical practices; particularly, avoidance of over-prescription and switching to a reduced-spectrum antibiotic once the results of drug susceptibility tests are available. Finally, daily inspection of the injection site is needed, as in all medical procedures that involve drug delivery.

Conclusion and implications

SC administration of antibiotics may be useful, reliable, economical, and easy to apply in various settings such as in-hospital care, long-term care facilities or ambulatory care. In some cases, the SC route for antibiotics may also be considered to facilitate hospital discharge in well selected patients. SC administration can optimize time above MIC but decreases C_{max} , hence “time dependent” antibiotics are probably the best candidates for this route. Further clinical studies are needed to assess the risks and benefits of SC administration in time-dependent antibiotics. Finally, SC administration should be considered during the development of new antimicrobial agents.

References

1. Yoshikawa TT, Norman DC. Geriatric Infectious Diseases: Current Concepts on Diagnosis and Management. *J Am Geriatr Soc.* 2017;65(3):631-641.
2. Corsonello A, Abbatecola AM, Fusco S, et al. The impact of drug interactions and polypharmacy on antimicrobial therapy in the elderly. *Clin Microbiol Infect.* 2015;21(1):20-26.
3. Beckett CL, Harbarth S, Huttner B. Special considerations of antibiotic prescription in the geriatric population. *Clin Microbiol Infect.* 2015;21(1):3-9.
4. Faulkner CM, Cox HL, Williamson JC. Unique aspects of antimicrobial use in older adults. *Clin Infect Dis.* 2005;40(7):997-1004.
5. Cockshott WP, Thompson GT, Howlett LJ, Seeley ET. Intramuscular or intralipomatous injections? *N Engl J Med.* 1982;307(6):356-358.
6. Forestier E, Paccalin M, Roubaud-Baudron C, et al. Subcutaneously administered antibiotics: a national survey of current practice from the French Infectious Diseases (SPILF) and Geriatric Medicine (SFGG) society networks. *Clin Microbiol Infect.* 2015;21(4):370.e371-373.
7. Robelet A, Caruba T, Corvol A, et al. [Antibiotics given subcutaneously to elderly]. *Presse Med.* 2009;38(3):366-376.
8. Fonzo-Christe C, Vukasovic C, Wasilewski-Rasca AF, Bonnabry P. Subcutaneous administration of drugs in the elderly: survey of practice and systematic literature review. *Palliat Med.* 2005;19(3):208-219.

9. Azevedo E, Barbosa L, Bortoli D, Cassiani SHdB. Administration of antibiotics subcutaneously: an integrative literature review. *Acta Paul Enferm.* 2012;25(5):817-822.
10. Colin E, Baldolli A, Verdon R, Saint-Lorant G. Subcutaneously administered antibiotics. *Med Mal Infect.* 2019 Jul 9 pii: S0399-077X(18)30775-3
11. McLennan DN, Porter CJ, Charman SA. Subcutaneous drug delivery and the role of the lymphatics. *Drug Discov Today Technol.* 2005;2(1):89-96.
12. Trevaskis NL, Kaminskas LM, Porter CJ. From sewer to saviour - targeting the lymphatic system to promote drug exposure and activity. *Nat Rev Drug Discov.* 2015;14(11):781-803.
13. Zuidema J, Kadir F, Titulaer HAC, Oussoren C. Release and absorption rates of intramuscularly and subcutaneously injected pharmaceuticals (II). *International Journal of Pharmaceutics.* 1994;105(3):189-207.
14. Jones GB, Collins DS, Harrison MW, et al. Subcutaneous drug delivery: An evolving enterprise. *Sci Transl Med.* 2017;9(405).
15. van Schaik IN, Bril V, van Geloven N, et al. Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet Neurol.* 2018;17(1):35-46.
16. Davies A, Berge C, Boehnke A, et al. Subcutaneous Rituximab for the Treatment of B-Cell Hematologic Malignancies: A Review of the Scientific Rationale and Clinical Development. *Adv Ther.* 2017;34(10):2210-2231.
17. Mackintosh CL, White HA, Seaton RA. Outpatient parenteral antibiotic therapy (OPAT) for bone and joint infections: experience from a UK

teaching hospital-based service. *J Antimicrob Chemother.* 2011;66(2):408-415.

18. Gabriel J. Subcutaneous fluid administration and the hydration of older people. *Br J Nurs.* 2014;23(14):S10, s12-14.

19. Caccialanza R, Constans T, Cotogni P, et al. Subcutaneous Infusion of Fluids for Hydration or Nutrition: A Review. *JPEN J Parenter Enteral Nutr.* 2018;42(2):296-307.

20. Jain S, Mansfield B, Wilcox MH. Subcutaneous fluid administration--better than the intravenous approach? *J Hosp Infect.* 1999;41(4):269-272.

21. Forbat L, Kunicki N, Chapman M, Lovell C. How and why are subcutaneous fluids administered in an advanced illness population: a systematic review. *J Clin Nurs.* 2017;26(9-10):1204-1216.

22. Slesak G, Schnurle JW, Kinzel E, et al. Comparison of subcutaneous and intravenous rehydration in geriatric patients: a randomized trial. *J Am Geriatr Soc.* 2003;51(2):155-160.

23. Remington R, Hultman T. Hypodermoclysis to treat dehydration: a review of the evidence. *J Am Geriatr Soc.* 2007;55(12):2051-2055.

24. Covinsky KE, Pierluissi E, Johnston CB. Hospitalization-associated disability: "She was probably able to ambulate, but I'm not sure". *Jama.* 2011;306(16):1782-1793.

25. El Samad Y, Lanoix JP, Bennis Y, et al. Tolerability and Plasma Drug Level Monitoring of Prolonged Subcutaneous Teicoplanin Treatment for Bone and Joint Infections. *Antimicrob Agents Chemother.* 2016;60(10):6365-6368.

26. Goutelle S, Valour F, Gagnieu MC, et al. Population pharmacokinetics and probability of target attainment of ertapenem administered by subcutaneous

or intravenous route in patients with bone and joint infection. *J Antimicrob Chemother.* 2018;73(4):987-994.

27. Roubaud-Baudron C, Forestier E, Fraisse T, et al. Tolerance of subcutaneously administered antibiotics: a French national prospective study. *Age Ageing.* 2017;46(1):151-155.
28. Gassler V, Stirnemann J, Huttner A, Prendki V. [Subcutaneous antibiotic administration in elderly patients]. *Rev Med Suisse.* 2014;10(446):1924, 1926-1929.
29. Noriega OD, Yarleque Leon SN. Antibiotics by Subcutaneous Route: A Safe and Efficient Alternative. *J Am Med Dir Assoc.* 2018;19(6):553-554.
30. Roubaud Baudron C, Legeron R, Ollivier J, et al. Is the subcutaneous route an alternative for administering ertapenem to older patients? PHACINERTA study. *Journal of Antimicrobial Chemotherapy.* 2019.
31. Lanbeck P, Odenholt I, Paulsen O. Antibiotics differ in their tendency to cause infusion phlebitis: a prospective observational study. *Scand J Infect Dis.* 2002;34(7):512-519.
32. Asin-Prieto E, Rodriguez-Gascon A, Isla A. Applications of the pharmacokinetic/pharmacodynamic (PK/PD) analysis of antimicrobial agents. *J Infect Chemother.* 2015;21(5):319-329.
33. Mouton JW, Dudley MN, Cars O, et al. Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs: an update. *J Antimicrob Chemother.* 2005;55(5):601-607.
34. Roberts JA, Kirkpatrick CM, Lipman J. Monte Carlo simulations: maximizing antibiotic pharmacokinetic data to optimize clinical practice for critically ill patients. *J Antimicrob Chemother.* 2011;66(2):227-231.

35. Jacobs MR. Optimisation of antimicrobial therapy using pharmacokinetic and pharmacodynamic parameters. *Clin Microbiol Infect.* 2001;7(11):589-596.
36. Available from: https://ec.europa.eu/health/documents/community-register/2014/20140321128084/anx_128084_en.pdf. Accessed.
37. Borner K, Lode H, Hampel B, et al. Comparative pharmacokinetics of ceftriaxone after subcutaneous and intravenous administration. *Chemotherapy.* 1985;31(4):237-245.
38. Bricaire F, Castaing JL, Pocidalo JJ, Vilde JL. [Pharmacokinetics and tolerance of ceftriaxone after subcutaneous administration]. *Pathol Biol (Paris).* 1988;36(5 Pt 2):702-705.
39. Harb G, Lebel F, Battikha J, Thackara JW. Safety and pharmacokinetics of subcutaneous ceftriaxone administered with or without recombinant human hyaluronidase (rHuPH20) versus intravenous ceftriaxone administration in adult volunteers. *Curr Med Res Opin.* 2010;26(2):279-288.
40. Gauthier D, Schambach S, Crouzet J, et al. Subcutaneous and intravenous ceftriaxone administration in patients more than 75 years of age. *Med Mal Infect.* 2014;44(6):275-280.
41. Muntendaum, P, Myers RL, Shearer TW. Pharmacokinetic response after subcutaneous administration of Ceftriaxone. IDWeek 2016; 2016; New Orleans, USA.
42. Melin-Coviaux F, Hary L, Hurtel AS, et al. Etude pharmaco-clinique comparative de la ceftriaxone par voie sous-cutanee et intraveineuse chez la personne agee. *Revue Geriatr.* 2000;25(5):337-347.

43. Centeno Cortes C, Galrica Neto I, Vara Hernando F. [Prospective study of subcutaneous ceftriaxone in patients on palliative care]. In: *Med Clin (Barc)*. Vol 130. Spain 2008:439.
44. Frasca D, Marchand S, Petitpas F, et al. Pharmacokinetics of ertapenem following intravenous and subcutaneous infusions in patients. *Antimicrob Agents Chemother*. 2010;54(2):924-926.
45. Ferry T, Senechal A, Gagnieu MC, et al. Prolonged subcutaneous high dose (1 g bid) of Ertapenem as salvage therapy in patients with difficult-to-treat bone and joint infection. *J Infect*. 2012;65(6):579-582.
46. Chauzy A, Grégoire N, Marchand S, Mimoz O. Appraisal of potential effect of subcutaneous administration on antibiotics pharmacokinetics-pharmacodynamics. ECCMID 2015; 2015; Copenhagen, Denmark.
47. Forestier E, Gros S, Peynaud D, et al. [Ertapenem administered intravenously or subcutaneously for urinary tract infections caused by ESBL producing enterobacteriaceae]. *Med Mal Infect*. 2012;42(9):440-443.
48. Kollef MH. Antibiotics for the critically ill: more than just selecting appropriate initial therapy. *Crit Care*. 2013;17(3):146.
49. Kuti JL, Kiffer CR, Mendes CM, Nicolau DP. Pharmacodynamic comparison of linezolid, teicoplanin and vancomycin against clinical isolates of *Staphylococcus aureus* and coagulase-negative staphylococci collected from hospitals in Brazil. *Clin Microbiol Infect*. 2008;14(2):116-123.
50. Peeters O, Ferry T, Ader F, et al. Teicoplanin-based antimicrobial therapy in *Staphylococcus aureus* bone and joint infection: tolerance, efficacy and experience with subcutaneous administration. *BMC Infect Dis*. 2016;16(1):622.

- 439 51. Destrem AL, Valour F, Ronde-Ousteau C, et al. Subcutaneous teicoplanin in
440 staphylococcal bone and joint infections. *Med Mal Infect.* 2019. Nov 3. pii:
441 S0399-077X(18)30695-4. doi: 10.1016/j.medmal.2019.10.002.
- 442 52. Cazaubon Y, Venisse N, Mimos O, et al. Population pharmacokinetics of
443 teicoplanin administered by subcutaneous or intravenous route and
444 simulation of optimal loading dose regimen. *J Antimicrob Chemother.*
445 2017;72(10):2804-2812.
- 446 53. Barbot A, Venisse N, Rayeh F, et al. Pharmacokinetics and
447 pharmacodynamics of sequential intravenous and subcutaneous teicoplanin
448 in critically ill patients without vasopressors. *Intensive Care Med.*
449 2003;29(9):1528-1534.
- 450 54. Carpentier E, Romeo B, El Samad Y, et al. [Subcutaneous teicoplanin for
451 children with infectious endocarditis]. *Arch Pediatr.* 2013;20(7):775-778.
- 452 55. Champoux N, Du Souich P, Ravaoarinoro M, et al. Single-dose
453 pharmacokinetics of ampicillin and tobramycin administered by
454 hypodermoclysis in young and older healthy volunteers. *Br J Clin*
455 *Pharmacol.* 1996;42(3):325-331.
- 456 56. Leng B, Saux MC, Latrille J. [Comparative pharmacokinetics of amikacin
457 after intravenous, intramuscular and subcutaneous administration]. *Nouv*
458 *Presse Med.* 1979;8(42):3421-3425.
- 459 57. Babinet P, Tancrede C, Bricaire F, et al. [Value of subcutaneous
460 tobramycin]. *Nouv Presse Med.* 1976;5(39):2640.
- 461 58. Courcol RJ, Pol A, Dufay C, et al. Pharmacokinetics of netilmicin
462 administered once or twice-daily by subcutaneous injection. *J Antimicrob*
463 *Chemother.* 1986;18(5):646-647.

59. Plantin P, Mahe M, Le Noac'h E, Le Roy JP. [Cutaneous necroses after subcutaneous injections of amikacin]. *Presse Med.* 1993;22(29):1366.
60. Doutre MS, Beylot C, Vendeaud-Busquet M, Bioulac-Sage P. [Cutaneous necrosis after subcutaneous administration of gentamycin]. *Therapie.* 1985;40(4):266-267.
61. Duterque M, Hubert-Asso AM, Corrad A. [Necrotic lesions caused by subcutaneous injections of gentamycin and sisomicin]. *Ann Dermatol Venereol.* 1985;112(9):707-708.
62. Penso D, Delfraissy JF, Pham Van T, Dormont J. [Skin necrosis following administration of subcutaneous gentamicin]. *Presse Med.* 1984;13(25):1575-1576.
63. Taillandier J, Manigand G, Fixy P, Dumont D. [Skin necrosis induced by subcutaneous gentamicin]. *Presse Med.* 1984;13(25):1574-1575.
64. Walker P, Neuhauser MN, Tam VH, et al. Subcutaneous administration of cefepime. *J Pain Symptom Manage.* 2005;30(2):170-174.
65. Matzneller P, Pokem PN, Capron A, et al. Temocillin pharmacokinetics in healthy volunteers. ECCMID 2017; 2017; Vienna, Austria.
66. Jin JF, Zhu LL, Chen M, et al. The optimal choice of medication administration route regarding intravenous, intramuscular, and subcutaneous injection. *Patient Prefer Adherence.* 2015;9:923-942.
67. Bookbinder LH, Hofer A, Haller MF, et al. A recombinant human enzyme for enhanced interstitial transport of therapeutics. *J Control Release.* 2006;114(2):230-241.

- 487 68. Constans T, Dutertre JP, Froge E. Hypodermoclysis in dehydrated elderly
488 patients: local effects with and without hyaluronidase. *J Palliat Care*.
489 1991;7(2):10-12.
- 490 69. Bruera E, Neumann CM, Pituskin E, Calder K, Hanson J. A randomized
491 controlled trial of local injections of hyaluronidase versus placebo in cancer
492 patients receiving subcutaneous hydration. *Ann Oncol*. 1999;10(10):1255-
493 1258.
- 494 70. Spandorfer PR, Mace SE, Okada PJ, et al. A randomized clinical trial of
495 recombinant human hyaluronidase-facilitated subcutaneous versus
496 intravenous rehydration in mild to moderately dehydrated children in the
497 emergency department. *Clin Ther*. 2012;34(11):2232-2245.
- 498 71. Ebihara T, Oshima S, Yasuda Y, et al. A survey of subcutaneous blood flow
499 in patients with SMID and subcutaneous ceftazidime administration using
500 mentholated warm compresses in healthy subjects. *J Int Med Res*.
501 2016;44(2):248-257.
- 502 72. Available from: [https://www.fda.gov/regulatory-information/search-fda-](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/nonclinical-safety-evaluation-reformulated-drug-products-and-products-intended-administration)
503 [guidance-documents/nonclinical-safety-evaluation-reformulated-drug-](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/nonclinical-safety-evaluation-reformulated-drug-products-and-products-intended-administration)
504 [products-and-products-intended-administration](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/nonclinical-safety-evaluation-reformulated-drug-products-and-products-intended-administration)
- 505 73. Freije I, Lamouche S, Tanguay M. Review of Drugs Approved via the
506 505(b)(2) Pathway: Uncovering Drug Development Trends and Regulatory
507 Requirements. *Ther Innov Regul Sci*. 2020 Jan;54(1):128-138 doi:
508 10.1177/2168479018811889
- 509 74. Pharmacokinetics and Safety of Antimicrobial Agents Administered by
510 Subcutaneous Route in Patients Aged Over 65 years (PhASAge) In.
511 ClinicalTrials.gov ID: NCT03583749

512 **Table 1. Summary of evidence and practical recommendations**

| Drug Categories | Summary of Evidence | Recommendations for clinicians |
|--|--|---|
| <ul style="list-style-type: none"> General considerations | <ul style="list-style-type: none"> SC use of antibiotics is associated with (<i>versus</i> IV): <ul style="list-style-type: none"> ↓ C_{max} ↑ T_{max} Similar AUCs (considering total absorption of antibiotic dose) Similar T>MIC.^{25-26, 30, 37-39, 41-42,44-45, 50, 52-53, 55-58} T>MIC is critical for “time-dependant” antibiotics C_{max}/MIC is critical for “concentration-dependant” antibiotics | <ul style="list-style-type: none"> SC route for time-dependent antibiotics like beta-lactams might be considered given their PK/PD properties. * SC route for concentration-dependent antibiotics like aminoglycosides should not be used given their PK/PD properties and a poor safety profile. * SC route might be considered after an initial IV loading phase, as IV remains the route for emergency. * SC route is reasonable as an initial option in patients with non-severe infections or patients in which other routes are not feasible / desirable. # The use of a flexible catheter, slow injection (> 5 minutes), and daily surveillance of the device may decrease the risk of local AEs. † Antibiotic dilution for SC or IV are the same † |
| <ul style="list-style-type: none"> Cephalosporins Time-dependent antibiotics Ceftriaxone++ Cefepime⁶⁴ Ceftazidime⁷¹ | <ul style="list-style-type: none"> Most of the available evidence comes from SC ceftriaxone. Bioavailability ≈100%. Trough level, AUC, and T>MIC are non-inferior to IV route.^{37-39, 41-42} Evidence from clinical use in hospitalization, ambulatory care, and palliative-care (including older population).^{6, 27, 29, 40, 42-43} Described as well tolerated, pain may be reduced by previous injection of lidocaine.^{37-40, 42, 43} Co-administration of SC antibiotics (ceftriaxone) with | <ul style="list-style-type: none"> SC use of ceftriaxone might be considered (similar bioavailability compared to the IV route with a good safety profile) * Other cephalosporins may be considered too but evidence is scarce. * |

| | | |
|--|--|---|
| | <p>recombinant hyaluronidase has been described to $\uparrow C_{max}$ and $\downarrow T_{max}$.³⁹</p> <ul style="list-style-type: none"> ○ Approximate number of individuals having received SC cephalosporins within the revised studies: 438 | |
| <ul style="list-style-type: none"> • Carbapenems • Time-dependent antibiotics <p>Ertapenem</p> | <ul style="list-style-type: none"> ○ Ertapenem is the main carbapenem studied for SC use. ○ Similar AUC, $T > MIC$ and PTA <i>versus</i> IV route.^{26, 30, 44-45} ○ Clinical studies in hospitalized and ambulatory patients with ESBL-E infections (including older population).^{6, 27, 29, 30, 44, 47} ○ Described as well tolerated, one reported case of skin necrosis.^{30, 27, 44, 45, 47} ○ Approximate number of individuals having received SC Ertapenem within the revised studies: 174 | <ul style="list-style-type: none"> ○ SC use of ertapenem might be considered (similar bioavailability compared to the IV route with a good safety profile). * |
| <ul style="list-style-type: none"> • Glycopeptides • Time-dependent antibiotics <p>Teicoplanin</p> | <ul style="list-style-type: none"> ○ \uparrow or $= C_{min}$ after loading phases.^{25, 50, 52, 53} ○ Clinical evidence for hospitalized and ambulatory patients with BJI, and anecdotal use for endocarditis.^{25, 27, 50, 52-54} ○ \uparrow rate of AEs reported with teicoplanin in comparison with other SC antibiotics.^{25, 27, 50, 53-54} ○ Approximate number of individuals having received SC Teicoplanin within the revised studies: 81 ○ Vancomycin is venotoxic | <ul style="list-style-type: none"> ○ SC teicoplanin might be considered (similar bioavailability compared to the IV route with a good safety profile). * ○ Vancomycin should not be used by SC route. † |
| <ul style="list-style-type: none"> • Aminoglycosides • Concentration dependent antibiotics <p>Tobramycin^{55, 57} Amikacin⁵⁶ Netilmicin⁵⁸ Gentamycin⁶⁰⁻⁶³</p> | <ul style="list-style-type: none"> ○ $\downarrow C_{max}$ and $\uparrow T_{max}$. Important caveat, as aminoglycosides are concentration-dependent antibiotics. ○ Comparable, or difficult to interpret bioavailability respect to the IV route.⁵⁵⁻⁵⁸ ○ Poor tolerability and diverse reports of cutaneous necrosis and painful ulcers.^{29, 55, 59-63} | <ul style="list-style-type: none"> ○ SC aminoglycosides should not be performed (poor safety profile and inappropriate PK/PD data) * |

513 AE, adverse effects; AUC, area under the curve; BJI: bone-joint infection; C_{max} , peak concentration; C_{min} , minimal plasma concentration; ESBL,
514 extended spectrum beta-lactamase; $T > MIC$, time for plasma concentration above the minimal inhibitory concentration; IV, intravenous; LOE: Level of

515 evidence; LTCF, long-term care facility; PD, pharmacodynamics; PK, pharmacokinetics; PTA, probability of target attainment; SC, subcutaneous; T_{max} ,
516 time to peak concentration.

- 517 ○ * Data derived from prospective studies (randomized, cross over or parallel groups)
- 518 ○ # Only case studies
- 519 ○ † Consensus of expert opinion based on clinical practice surveys

520

521

522 **Legends to Figures**

523 **Figure 1:** illustration of plasma concentration profile of drugs administered by intravenous (IV) and
524 subcutaneous (SC) infusion. C_{max} , peak concentration; T_{max} , time to peak concentration; MIC,
525 minimal inhibitory concentration.




Figure 1.